Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial
<br><strong>Background: </strong>Antiretroviral therapy (ART) cannot cure HIV infection because of a persistent reservoir of latently infected cells. Approaches that force HIV transcription from these cells, making them susceptible to killing—termed kick and kill regimens—have been...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Elsevier
2020
|
| _version_ | 1797062378889674752 |
|---|---|
| author | Fidler, S Stöhr, W Pace, M Dorrell, L Lever, A Pett, S Kinloch-de Loes, S Fox, J Clarke, A Nelson, M Thornhill, J Khan, M Fun, A Bandara, M Kelly, D Kopycinski, J Hanke, T Yang, H Bennett, R Johnson, M Howell, B Barnard, R Wu, G Kaye, S Wills, M Babiker, A Frater, J RIVER trial study group |
| author_facet | Fidler, S Stöhr, W Pace, M Dorrell, L Lever, A Pett, S Kinloch-de Loes, S Fox, J Clarke, A Nelson, M Thornhill, J Khan, M Fun, A Bandara, M Kelly, D Kopycinski, J Hanke, T Yang, H Bennett, R Johnson, M Howell, B Barnard, R Wu, G Kaye, S Wills, M Babiker, A Frater, J RIVER trial study group |
| author_sort | Fidler, S |
| collection | OXFORD |
| description | <br><strong>Background: </strong>Antiretroviral therapy (ART) cannot cure HIV infection because of a persistent reservoir of latently infected cells. Approaches that force HIV transcription from these cells, making them susceptible to killing—termed kick and kill regimens—have been explored as a strategy towards an HIV cure. RIVER is the first randomised trial to determine the effect of ART-only versus ART plus kick and kill on markers of the HIV reservoir.</br>
<br><strong>Methods: </strong>This phase 2, open-label, multicentre, randomised, controlled trial was undertaken at six clinical sites in the UK. Patients aged 18–60 years who were confirmed as HIV-positive within a maximum of the past 6 months and started ART within 1 month from confirmed diagnosis were randomly assigned by a computer generated randomisation list to receive ART-only (control) or ART plus the histone deacetylase inhibitor vorinostat (the kick) and replication-deficient viral vector T-cell inducing vaccines encoding conserved HIV sequences ChAdV63. HIVconsv-prime and MVA.HIVconsv-boost (the kill; ART + V + V; intervention). The primary endpoint was total HIV DNA isolated from peripheral blood CD4+ T-cells at weeks 16 and 18 after randomisation. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, NCT02336074.</br>
<br><strong>Findings: </strong>Between June 14, 2015 and Jul 11, 2017, 60 men with HIV were randomly assigned to receive either an ART-only (n=30) or an ART + V + V (n=30) regimen; all 60 participants completed the study, with no loss-to-follow-up. Mean total HIV DNA at weeks 16 and 18 after randomisation was 3·02 log10 copies HIV DNA per 106 CD4+ T-cells in the ART-only group versus 3·06 log10 copies HIV DNA per 106 CD4+ T-cells in ART + V + V group, with no statistically significant difference between the two groups (mean difference of 0·04 log10 copies HIV DNA per 106 CD4+ T-cells [95% CI −0·03 to 0·11; p=0·26]). There were no intervention-related serious adverse events.</br>
<br><strong>Interpretation: </strong>This kick and kill approach conferred no significant benefit compared with ART alone on measures of the HIV reservoir. Although this does not disprove the efficacy kick and kill strategy, for future trials enhancement of both kick and kill agents will be required.</br> |
| first_indexed | 2024-03-06T20:44:42Z |
| format | Journal article |
| id | oxford-uuid:357b2fe3-4431-400b-a1cf-c26d3e056bcc |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T20:44:42Z |
| publishDate | 2020 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:357b2fe3-4431-400b-a1cf-c26d3e056bcc2022-03-26T13:32:17ZAntiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trialJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:357b2fe3-4431-400b-a1cf-c26d3e056bccEnglishSymplectic ElementsElsevier2020Fidler, SStöhr, WPace, MDorrell, LLever, APett, SKinloch-de Loes, SFox, JClarke, ANelson, MThornhill, JKhan, MFun, ABandara, MKelly, DKopycinski, JHanke, TYang, HBennett, RJohnson, MHowell, BBarnard, RWu, GKaye, SWills, MBabiker, AFrater, JRIVER trial study group<br><strong>Background: </strong>Antiretroviral therapy (ART) cannot cure HIV infection because of a persistent reservoir of latently infected cells. Approaches that force HIV transcription from these cells, making them susceptible to killing—termed kick and kill regimens—have been explored as a strategy towards an HIV cure. RIVER is the first randomised trial to determine the effect of ART-only versus ART plus kick and kill on markers of the HIV reservoir.</br> <br><strong>Methods: </strong>This phase 2, open-label, multicentre, randomised, controlled trial was undertaken at six clinical sites in the UK. Patients aged 18–60 years who were confirmed as HIV-positive within a maximum of the past 6 months and started ART within 1 month from confirmed diagnosis were randomly assigned by a computer generated randomisation list to receive ART-only (control) or ART plus the histone deacetylase inhibitor vorinostat (the kick) and replication-deficient viral vector T-cell inducing vaccines encoding conserved HIV sequences ChAdV63. HIVconsv-prime and MVA.HIVconsv-boost (the kill; ART + V + V; intervention). The primary endpoint was total HIV DNA isolated from peripheral blood CD4+ T-cells at weeks 16 and 18 after randomisation. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, NCT02336074.</br> <br><strong>Findings: </strong>Between June 14, 2015 and Jul 11, 2017, 60 men with HIV were randomly assigned to receive either an ART-only (n=30) or an ART + V + V (n=30) regimen; all 60 participants completed the study, with no loss-to-follow-up. Mean total HIV DNA at weeks 16 and 18 after randomisation was 3·02 log10 copies HIV DNA per 106 CD4+ T-cells in the ART-only group versus 3·06 log10 copies HIV DNA per 106 CD4+ T-cells in ART + V + V group, with no statistically significant difference between the two groups (mean difference of 0·04 log10 copies HIV DNA per 106 CD4+ T-cells [95% CI −0·03 to 0·11; p=0·26]). There were no intervention-related serious adverse events.</br> <br><strong>Interpretation: </strong>This kick and kill approach conferred no significant benefit compared with ART alone on measures of the HIV reservoir. Although this does not disprove the efficacy kick and kill strategy, for future trials enhancement of both kick and kill agents will be required.</br> |
| spellingShingle | Fidler, S Stöhr, W Pace, M Dorrell, L Lever, A Pett, S Kinloch-de Loes, S Fox, J Clarke, A Nelson, M Thornhill, J Khan, M Fun, A Bandara, M Kelly, D Kopycinski, J Hanke, T Yang, H Bennett, R Johnson, M Howell, B Barnard, R Wu, G Kaye, S Wills, M Babiker, A Frater, J RIVER trial study group Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial |
| title | Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial |
| title_full | Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial |
| title_fullStr | Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial |
| title_full_unstemmed | Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial |
| title_short | Antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach, on measures of the HIV reservoir in participants with recent HIV infection (the RIVER trial): a phase 2, randomised trial |
| title_sort | antiretroviral therapy alone versus antiretroviral therapy with a kick and kill approach on measures of the hiv reservoir in participants with recent hiv infection the river trial a phase 2 randomised trial |
| work_keys_str_mv | AT fidlers antiretroviraltherapyaloneversusantiretroviraltherapywithakickandkillapproachonmeasuresofthehivreservoirinparticipantswithrecenthivinfectiontherivertrialaphase2randomisedtrial AT stohrw antiretroviraltherapyaloneversusantiretroviraltherapywithakickandkillapproachonmeasuresofthehivreservoirinparticipantswithrecenthivinfectiontherivertrialaphase2randomisedtrial AT pacem antiretroviraltherapyaloneversusantiretroviraltherapywithakickandkillapproachonmeasuresofthehivreservoirinparticipantswithrecenthivinfectiontherivertrialaphase2randomisedtrial AT dorrelll antiretroviraltherapyaloneversusantiretroviraltherapywithakickandkillapproachonmeasuresofthehivreservoirinparticipantswithrecenthivinfectiontherivertrialaphase2randomisedtrial AT levera antiretroviraltherapyaloneversusantiretroviraltherapywithakickandkillapproachonmeasuresofthehivreservoirinparticipantswithrecenthivinfectiontherivertrialaphase2randomisedtrial AT petts antiretroviraltherapyaloneversusantiretroviraltherapywithakickandkillapproachonmeasuresofthehivreservoirinparticipantswithrecenthivinfectiontherivertrialaphase2randomisedtrial AT kinlochdeloess antiretroviraltherapyaloneversusantiretroviraltherapywithakickandkillapproachonmeasuresofthehivreservoirinparticipantswithrecenthivinfectiontherivertrialaphase2randomisedtrial AT foxj antiretroviraltherapyaloneversusantiretroviraltherapywithakickandkillapproachonmeasuresofthehivreservoirinparticipantswithrecenthivinfectiontherivertrialaphase2randomisedtrial AT clarkea antiretroviraltherapyaloneversusantiretroviraltherapywithakickandkillapproachonmeasuresofthehivreservoirinparticipantswithrecenthivinfectiontherivertrialaphase2randomisedtrial AT nelsonm antiretroviraltherapyaloneversusantiretroviraltherapywithakickandkillapproachonmeasuresofthehivreservoirinparticipantswithrecenthivinfectiontherivertrialaphase2randomisedtrial AT thornhillj antiretroviraltherapyaloneversusantiretroviraltherapywithakickandkillapproachonmeasuresofthehivreservoirinparticipantswithrecenthivinfectiontherivertrialaphase2randomisedtrial AT khanm antiretroviraltherapyaloneversusantiretroviraltherapywithakickandkillapproachonmeasuresofthehivreservoirinparticipantswithrecenthivinfectiontherivertrialaphase2randomisedtrial AT funa antiretroviraltherapyaloneversusantiretroviraltherapywithakickandkillapproachonmeasuresofthehivreservoirinparticipantswithrecenthivinfectiontherivertrialaphase2randomisedtrial AT bandaram antiretroviraltherapyaloneversusantiretroviraltherapywithakickandkillapproachonmeasuresofthehivreservoirinparticipantswithrecenthivinfectiontherivertrialaphase2randomisedtrial AT kellyd antiretroviraltherapyaloneversusantiretroviraltherapywithakickandkillapproachonmeasuresofthehivreservoirinparticipantswithrecenthivinfectiontherivertrialaphase2randomisedtrial AT kopycinskij antiretroviraltherapyaloneversusantiretroviraltherapywithakickandkillapproachonmeasuresofthehivreservoirinparticipantswithrecenthivinfectiontherivertrialaphase2randomisedtrial AT hanket antiretroviraltherapyaloneversusantiretroviraltherapywithakickandkillapproachonmeasuresofthehivreservoirinparticipantswithrecenthivinfectiontherivertrialaphase2randomisedtrial AT yangh antiretroviraltherapyaloneversusantiretroviraltherapywithakickandkillapproachonmeasuresofthehivreservoirinparticipantswithrecenthivinfectiontherivertrialaphase2randomisedtrial AT bennettr antiretroviraltherapyaloneversusantiretroviraltherapywithakickandkillapproachonmeasuresofthehivreservoirinparticipantswithrecenthivinfectiontherivertrialaphase2randomisedtrial AT johnsonm antiretroviraltherapyaloneversusantiretroviraltherapywithakickandkillapproachonmeasuresofthehivreservoirinparticipantswithrecenthivinfectiontherivertrialaphase2randomisedtrial AT howellb antiretroviraltherapyaloneversusantiretroviraltherapywithakickandkillapproachonmeasuresofthehivreservoirinparticipantswithrecenthivinfectiontherivertrialaphase2randomisedtrial AT barnardr antiretroviraltherapyaloneversusantiretroviraltherapywithakickandkillapproachonmeasuresofthehivreservoirinparticipantswithrecenthivinfectiontherivertrialaphase2randomisedtrial AT wug antiretroviraltherapyaloneversusantiretroviraltherapywithakickandkillapproachonmeasuresofthehivreservoirinparticipantswithrecenthivinfectiontherivertrialaphase2randomisedtrial AT kayes antiretroviraltherapyaloneversusantiretroviraltherapywithakickandkillapproachonmeasuresofthehivreservoirinparticipantswithrecenthivinfectiontherivertrialaphase2randomisedtrial AT willsm antiretroviraltherapyaloneversusantiretroviraltherapywithakickandkillapproachonmeasuresofthehivreservoirinparticipantswithrecenthivinfectiontherivertrialaphase2randomisedtrial AT babikera antiretroviraltherapyaloneversusantiretroviraltherapywithakickandkillapproachonmeasuresofthehivreservoirinparticipantswithrecenthivinfectiontherivertrialaphase2randomisedtrial AT fraterj antiretroviraltherapyaloneversusantiretroviraltherapywithakickandkillapproachonmeasuresofthehivreservoirinparticipantswithrecenthivinfectiontherivertrialaphase2randomisedtrial AT rivertrialstudygroup antiretroviraltherapyaloneversusantiretroviraltherapywithakickandkillapproachonmeasuresofthehivreservoirinparticipantswithrecenthivinfectiontherivertrialaphase2randomisedtrial |